Blatt Lawrence Insider Trades

Insider Trading History

Track insider trading activity for Blatt Lawrence. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Aligos Therapeutics
Aligos Therapeutics ALGS
President And CEO
Holding Value $646k 105,840 shares
Last Trade
Mar 09, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$744k 105,840 shares
$7.03
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
President And CEO
Holding Value $1.1M 179,800 shares
Last Trade
Jul 16, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.56M 179,800 shares
$8.68
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
President And CEO
Holding Value $855k 140,103 shares
Last Trade
Feb 28, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.36M 140,103 shares
$16.87
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $207k 33,920 shares
Last Trade
Sep 04, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$398k 33,920 shares
$11.74
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $5.89M 965,435 shares
Last Trade
Mar 01, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$27.3M 965,435 shares
$28.25
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $1.41M 230,999 shares
Last Trade
Feb 28, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$10.1M 421,100 shares
$24.00
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $0 0 shares
Last Trade
Feb 27, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$12.6M 530,850 shares
$23.75
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $11.3M 1,847,575 shares
Last Trade
Oct 25, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$14.1M 915,415 shares
$15.37
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $916k 150,000 shares
Last Trade
Sep 08, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$3.15M 150,000 shares
$21.00
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $1.48M 242,500 shares
Last Trade
Mar 15, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$8.12M 242,500 shares
$33.50
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $987k 161,700 shares
Last Trade
Jul 07, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.7M 161,700 shares
$35.25
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $1.97M 323,400 shares
Last Trade
Feb 04, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$30.9M 404,250 shares
$76.50
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $2.75M 450,000 shares
Last Trade
Dec 01, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$182M 450,000 shares
$404.50
$6.10
Aligos Therapeutics
Aligos Therapeutics ALGS
Chief Executive Officer
Holding Value $7.55M 1,237,298 shares
Last Trade
Oct 15, 2020 Sale
No data
No data
$6.10

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up